No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NTLA240517C20000
- 4.30
- +0.15+3.61%
15min DelayTrading May 9 11:51 ET
4.30High4.30Low
4.30Open4.15Pre Close1 Volume64 Open Interest20.00Strike Price430.00Turnover0.00%IV-0.36%PremiumMay 17, 2024Expiry Date4.74Intrinsic Value100Multiplier8DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma5.32Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
Express News | Intellia Therapeutics Inc - Cash Position Is Expected to Fund Operations Into Late 2026.
Express News | Intellia Therapeutics Inc - on Track to Initiate Phase 3 Study of Ntla-2002 for Treatment of Hereditary Angioedema (Hae) in 2H 2024
Express News | Intellia Therapeutics' Q1 Cash, Cash Equivalents And Marketable Securities Were $953.4M Expected To Provide Cash Runway Into Late 2026
Express News | Intellia Therapeutics Q1 2024 GAAP EPS $(1.12) Beats $(1.39) Estimate, Sales $28.935M Beat $11.504M Estimate
Express News | Intellia Therapeutics Q1 Collaboration Revenue USD 28.935 Million
Express News | Intellia Therapeutics Q1 Operating Expenses USD 142.938 Million
Comments
If you had invested $10,000 in Cathie Wood's $ARK Innovation ETF(ARKK.US$ and Warren Buffett's Berkshire Hathaway $Berkshire Hathaway-B(BRK.B.US$ at different time frames here's how much you'd have today.
When $ARKK launched in 2014
Total Returns:
$BRK.B $28.6K
$ARKK $27.4K
5 years ago
Total Returns:
$BRK.B $19.7K
$ARKK $11.7K
3 years ago
Total Returns:
$BRK.B $16.4K
$ARKK $3.3K
1 year ago
Total Returns:
$BRK.B $12.8K
$ARKK $12.4K
At the start of 2024
Total Returns:
$BR...
When $ARKK launched in 2014
Total Returns:
$BRK.B $28.6K
$ARKK $27.4K
5 years ago
Total Returns:
$BRK.B $19.7K
$ARKK $11.7K
3 years ago
Total Returns:
$BRK.B $16.4K
$ARKK $3.3K
1 year ago
Total Returns:
$BRK.B $12.8K
$ARKK $12.4K
At the start of 2024
Total Returns:
$BR...
+3
2
2
Insiders selling shares at low prices may signal expected stock weakness. The absence of insider buying and increased selling over the past year suggest the shares aren't cheap, making the company a cautious investment.
1
The first treatment based on CRISPR technology is poised to win FDA approval next month, offering hope to patients and opportunities to investors.
"A turning point in medicine"
Scientists have made significant progress in treating thousands of illnesses over the years, but finding cures for rare and deadly diseases remains a significant challenge. While treatments for inherited conditions like sickle cell...
"A turning point in medicine"
Scientists have made significant progress in treating thousands of illnesses over the years, but finding cures for rare and deadly diseases remains a significant challenge. While treatments for inherited conditions like sickle cell...
19
2
Read more